AVH - AVITA Medical, Inc

[sam76]

This is the new identity of the merger between VSG and CCE

Market
capitalisation:
$9.06m

Shares on issue:
$93.47m

Cash balance:
$8.7m (as at 30 April 2008)

a market cap of 9 million with nearly all of that in cash

Really puts no value on their projects (Funhaler and re-cell)

very tightly held company at the moment, I've been trying to get in for a couple of weeks but no one is selling.




ABOUT AVITA MEDICAL LIMITED Avita Medical Limited is a publicly listed biomedical company that is evolving to become a global medical device company. The merger with Visiomed Group Ltd was completed in February 2008 and following the merger the company is now active in the regenerative medicine and respiratory
markets.


Regenerative Medicine

The company develops and distributes tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissue culture/collection technology, the company is able to provide innovative treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.

ReCell ®(www.recell.info) is a stand-alone, rapid cell harvesting device that enables surgeons to treat skin defects using the patient's own cells that are collected during surgery. The surgeon can prepare a small quantity of cells within 30 minutes on site rather than having to send a biopsy to the
laboratory. ReCell ®has been designed for use in a wide variety of plastic, reconstructive and cosmetic procedures. ReCell ®is gaining acceptance in a number of indications including Vitiligo, a common skin pigmentation disease.

ReCell ®is approved for sale in Australia, Brazil, Canada, Chile, Croatia, European Union, Hong Kong, Israel, Japan, Malaysia, New Zealand, Norway, Singapore, South Africa, Switzerland and Turkey. The company is currently focused on securing FDA approval for sale of the product in the
USA.

Respiratory

The company commercialises innovative medical technologies for improved medication delivery and adherence in patients suffering from chronic respiratory diseases. The company manufactures and sells a range of spacers for the paediatric, adolescent and adult market and is the leading provider
of spacers in Australia.

The Funhaler ®incentive asthma spacer has been designed specifically for the paediatric market, incorporating auditory and visual incentives to encourage children to comply with their medication plan. Clinically demonstrated to improve compliance to prescribed medication by 38% and increase
proper inhalation technique in children by 60%. The Funhaler ®is patented, CE marked for the EU, FDA cleared for the US and TGA registered in Australia.

Breath-A-Tech is the leading spacer for adolescents and adults in Australia. The product is effective, compact, easy to use and competitively priced. The Breath-A-Tech hospital-grade spacer can also be autoclaved in the hospital or clinical setting.

 

[sam76]

Re: AVH - Avita Medical Limited

volume up and heading in the right direction (even today)

broken through short term resistance and seems to be heading up again.

lot's of cashola in the bank and only 90 million shares on issue.

 

[sam76]

up another 30% to 8.4 cents.

Announcement out this morning can't be the reason for the interest.

buyers are steppin up quicker as the day moves on.

anyone else follow this one?

only 90 million shares on issue

 

[sam76]

Hey Sam, how's it going?

Not too bad, Sam. And you?

Yeah, very well thanks

Well it closed on its high yesterday with increasing volume over the last week.

Mind you 500 odd k is nothing to get excited about it's the tightly held register that gets me excited

Here's another chart.

 

[sam76]

Just hit 10 cents.

I'm wondering if it's to do with the funhaler or maybe recell.

It woould make more sense if it were funhaler related...

 

[sam76]

well this one has started running again.

Plenty of buyers chasing this one up.

Seemed to be a bit of a leaky boat last time with the recell announcement.

perhaps history is repeating itself.

 

[stevenc]

Gday Sam I bought some of these a few weeks back at .063. Looks like the products they are selling are gaining acceptance quickly in the medical industry with some very good reviews and with the ISO rating recently more markets are going to be opened up for them. Want to keep these for awhile and see what they do, potential for sales in the fields they treat are huge imo. Your right though the shares dont trade to quickly with this listing and can be hard to get in.

 

[sam76]

G'day Steven.

nice to see you here.

Well AVH has delivered a 600k per year cost saving review and doubled the shelf life of their regen stuff.

opening at 12 cents with support this morning.

 

[stevenc]

That was a great start to the day @.12c shame it didnt hold . Good to see some positive news from a company for a change.

 

[sam76]

To the more experienced.

is this showing signs of a cup and handle?

or has the handle part not been long enough?

or am i seeing things that aren't there?

 

[sam76]

Another grant awarded.

This time from The US Miltary for 2 million

Shares pass through 10.5 resistance convincingly.

90 million shares on issue and 5 (or is it 7) million in the bank (not including the latest grant)

 

[DVEOUS]

This dog of a stock has a long way to go.
I paid $0.356 (average) for my Cynical Cell Culture shares, and after the 10:1, that equates to $3.56 per share.

So are we all just waiting around for them to rise by $3.45 ish per share?

 

[DVEOUS]

Either the search is broken, or nobody has created an AVH topic before?

Anyway, it looks like the mongrel dog CCE Cynical Cell Culture that was transformed into the AVH penny dreadful might begin to redeem itself.

Last week they announced receipt of US$400k (of the US$1.45m) from the US Department of Defense, as a beginning of the "AFIRM" study.

This morning they announce AVH has secured regulatory approval for its
ReCell ® Autologous Spray-On Skin from the Chinese State Food and Drug Administration (SFDA).

Things are looking up for long time CCE investors.
I don't know about you, but I bought CCE at a DCA of $0.35.
After the name change/merge with Visiomed and 1:10 consolidation, that equates to $3.50 a share.
Currently at $0.115, they have a hell of long run to get back to where they were.

 

[sam76]

Gotta love picking a whole lot of these ppuupys up at 4 cents

This is a big feather in the recell cap.

 

[sam76]

The story gets better and better.

US RECELL SPRAY-ON-SKIN ENROLMENT COMMENCES

· First US patient receives ReCell ® Spray-On-Skin treatment
· Results demonstrate accelerated healing and reduced pain with ReCell ®
· Other sites to soon commence treating patients with ReCell ®
· Trial approved by US FDA and sponsored by US defense forces

10 June 2010, Avita Medical Ltd (ASX: AVH): In an important milestone for Avita Medical the first United States-based treatment of a patient with ReCell ® under the approved FDA protocol was conducted. The treatment of a burns victim on 27 May 2010 was at Wake Forest University Baptist
Medical Burn Center in Winston-Salem, North Carolina.

The patient presented with burns on both arms; burn sites were arbitrarily labelled “A” and “B” per protocol. Through the protocol’s blinded randomisation process one site was assigned treatment with ReCell ®, the other served as a control and was treated with split thickness skin graft, the
current standard of care.

On seven-day follow-up the patient had excellent results: the ReCell ® graft site had 100% take and was fully re-epithelialised (i.e., the treated wound was completely covered with new skin with no open areas or blisters). In contrast, the control site had 75-80% take with 20-25% of the area having unhealed open interstices. Similarly, the ReCell ® donor site was 100% closed and fully reepithelialised whereas the control traditional graft donor site on the thigh remained open and slightly oozy with numerous bleeding spots. Critically, in self-reporting of pain, the patient reported 0/10 pain at the ReCell ® site and 10/10 pain at the traditional control site.

“We are very pleased but not surprised by the excellent outcome,” said Dr William Dolphin, CEO Avita Medical. “The ReCell Spray-On-Skin technology offers great benefits to the patient and clinicians and has the potential to deliver significant cost savings to the healthcare system.”
Under the revised and approved FDA protocol ReCell ® Spray-On-Skin and the AFIRM defense forces sponsored study has attracted national and international attention. Television network CNN filmed the procedure for an upcoming production describing new frontier products in regenerative medicine and will continue to follow patients treated with ReCell ®.

 

[DVEOUS]

The story gets better and better.

LOL!
It couldn't get much worse.

Don't forget, to compare apples with apples, AVH need to get to $3.00 per share.

CCE was trading in the region of $0.30 per share before the 10:1.

So, this dog of a stock has a long way to go, as any long holding CCE "investor" knows.

 

[sam76]

CCE would have been bankrupt by now if VSG hadn't merged with them.



bitter for hanging on or just plain mopey?

Actually, This bloke answers your whinge better I.

With respect, they don't need to get back anywhere. What they need to do is secure key investment funding support (La Jolla Cove/Fortrend) while at the same developing Tier 1 industry partnerships (AFIRM) to help gain the necessary regulatory approvals (FDA/SFDA/Taiwan/France etc.) in the biggest markets that offer the best potential for high volume sales, and that's exactly what they are doing.

No point in banging on about the past, it's done and dusted, and none of it was done under the current executive leadership. As for the company having a long way to go, so what? Would you have preferred CCE to fail, which it very nearly did? At least you now have a chance to recoup any losses you may have incurred, and that opportunity is entirely due to the work that has been done by Bill Dolphin and the new executive since they implemented the successful merger of CCE/VSG...I say credit where it's due and let them get on with the good work.

 

[pezzer]

this stock doesnt seem to be going anywhere.

Anyone have any idea how the clinical trials are going?

I'm in it for the long haul buying at around 10cents a while ago, but it has just been totally flat.

 

[reeftip]

Started talking about this one on another thread (Suhm’s Birds of a feather) but I didn’t want to hijack it by going too off topic talking about this company.

For many years AVH was a dog. Times have changed, a new CEO with runs on the board and now the company is finally making money.

FDA approval is progressing nicely and should hopefully be in place by June next year at the latest.

Here are a couple of clips
http://www.azfamily.com/news/health/sprayonskin-117546243.html
http://www.onemedplace.com/onemedtv/play.php?vid=1808


Anyway I like to story.

Disclosure: Stock held

 

[reeftip]

They won the 2011 Best of What's New Award from Popular Science in the Health category last December.

Here is a good article

http://www.thesun.co.uk/sol/homepage/features/4137266/Burns-tot-has-spray-on-skin-cure.html

Pretty amazing before and after photos